HCPLive Network

Higher Dose of Fulvestrant Associated With Improved Survival in Advanced Breast Cancer

Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

Click here to view this article.


Further Reading

A study from Norway suggests some breast cancers detected by routine screening might spontaneously regress if left untreated.

New data from the Netherlands suggest that young patients who undergo post-lumpectomy radiotherapy using tangential fields have an increased risk of cancer arising in the other breast.
Sentinel lymph node surgery may provide a less-invasive alternative to axillary lymph node dissection for nodal staging in node-positive breast cancer.
Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.
Herceptin plus docetaxel/cyclophosphamide (HER TC) adjuvant therapy—a non-anthracycline-containing regimen—was tolerable with acceptable safety for lower risk patients with HER2-positive early breast cancer, according to a large Phase II study.
Multiple studies presented at the San Antonio Breast Cancer Symposium report encouraging findings on the role of aromatase inhibitors in treating postmenopausal women with early-stage estrogen receptor-positive breast cancer.
Multiple studies presented at the San Antonio Breast Cancer Symposium report encouraging findings on the role of aromatase inhibitors in treating postmenopausal women with early-stage estrogen receptor-positive breast cancer.
More Reading